Tina M. Landess, CCRA

Director

Tina has more than 12 years of experience with clinical trials as both a consultant and permanent employee of Roche Molecular Systems, BioMedicines, Bayer Diagnostics, Chiron and most recently, Vermillion. Her clinical trial management experience builds on another six years of experience researching and developing products, primarily within the diagnostic field.

Tina has been involved in numerous successful clinical trials spanning the US, Canada, EU, and ROW (rest of world). She has worked with companies designing Analytical Studies, Studies for 510(k) Submissions, Studies for Pre-Market Application Submissions, and Post Marketing Studies.

Tina holds a BA in Chemistry from Arizona State University and received her Certification of Clinical Research Associates (CCRA) in 2001.

Capabilities Document »

Blogs by Tina Landess »

All Myraqa Bios »

Share / Follow



Recent Blogs

Great New Companion Diagnostics E-Book Released Today A valuable resource in a hot, but under-informed segment of the market
Oragene Clearance Shows DNA Stabilization is Class II Clearance could have a significant impact on DTCG providers
My Screening Test for Screening Tests Offering up a rare bit of regulatory certainty
The Abolish OIVD Act of 2011 A torches-and-pitchforks approach to LDT regulations

Glossary Terms

510(k)
Clinical Research Associate (CRA)